Vnitr Lek 2011, 57(4):368-371

Diabetes mellitus and the liver cirrhosis

T. Fejfar1,*, V. Šafka2, V. Jirkovský1, J. Štefánková3, P. Hůlek1
1 II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
2 Ústav fyziologie Lékařské fakulty Hradec Králové, přednostka prof. MUDr. Zuzana Červinková, CSc.
3 Diabetologická ambulance Hradec Králové

Patients with liver cirrhosis have increased risk of diabetes mellitus development, especially when the underlying disease is hereditary hemochromatosis, autoimune hepatitis, non-alcoholic steatohepatitis or chronic hepatitis C. Patients with associated diabetes according to liver cirrhosis complications have worse prognosis and the therapy is influenced by both diseases. The authors bring short review of particular diseases, diagnosis and treatment strategy.

Keywords: liver cirrhosis; diabetes mellitus

Received: October 31, 2010; Published: April 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fejfar T, Šafka V, Jirkovský V, Štefánková J, Hůlek P. Diabetes mellitus and the liver cirrhosis. Vnitr Lek. 2011;57(4):368-371.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bianchi G, Marchesini G, Zoli M et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-125. Go to original source... Go to PubMed...
    2. Lai MS, Hsieh MS, Chiu YH et al. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295-1302. Go to original source... Go to PubMed...
    3. Donadon V, Balbi M, Mas MD et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-758. Go to original source... Go to PubMed...
    4. Horák J. Genetická hemochromatóza. In: Ehrmann J, Hůlek P et al (eds). Hepatologie. 1. vyd. Praha: Grada 2010: 339-345.
    5. DuBois S, Kowdley V. Review article: targeted screening for hereditary haemochromatosis in high-risc groups. Aliment Pharmacol Ther 2004; 20: 1-14. Go to original source... Go to PubMed...
    6. Aytug S, Reich D, Sapiro LE et al. Impaired IRS-1/PI3-kinase signalling in patients with HCV: a mechanism for increase prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-1392. Go to original source... Go to PubMed...
    7. Alaei M, Negro R. Hepatitis C virus and glucose and lipid metabolism. Diabetes Metab 2008; 34: 692-700. Go to original source... Go to PubMed...
    8. Romeo-Gómez M, Fernández-Rodriguez CM, Andrare RJ at al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721-727. Go to original source... Go to PubMed...
    9. Donadon V, Balbi M, Ghersetti M et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15: 2506-2511. Go to original source... Go to PubMed...
    10. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240. Go to original source... Go to PubMed...
    11. Salpeter SR, Greyber E, Pasternak GA et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 20: CD002967. Go to original source... Go to PubMed...
    12. Romero-Gómez M, Diago M, Andrade RJ et al. Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-1708. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.